FDA Approves Adaptive Deep Brain Stimulation for Parkinson’s Treatment

The new technology dynamically adjusts brain stimulation in real-time, offering personalized symptom management for Parkinson’s patients.

The FDA has approved Medtronic's BrainSense Adaptive deep brain stimulation (aDBS), a groundbreaking device that customizes stimulation based on real-time brain activity.
Unlike traditional continuous DBS, aDBS monitors brain signals and adjusts stimulation to prevent overtreatment or undertreatment of motor symptoms like tremors and stiffness.
The system includes two algorithms targeting the subthalamic nucleus: one provides instant symptom suppression, while the other maintains stable brain activity.
The adaptive technology represents decades of research and could pave the way for future AI-driven treatment of non-motor symptoms like depression and insomnia.
Patients report significant symptom relief, reduced reliance on medications, and improved quality of life, including the ability to resume activities like running marathons.